- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement | 405 | ACCESS Newswire | The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd.(NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage... ► Artikel lesen | |
| 10.03. | NLS Pharmaceutics kündigt Fusion mit Kadimastem an | 2 | Investing.com Deutsch | ||
| 25.02. | NLS Pharmaceutics Ltd.; Kadimastem Ltd.: Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment | 270 | PR Newswire | Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH and NESS ZIONA, Israel... ► Artikel lesen | |
| 10.02. | NLS und Kadimastem planen Fusion für Innovation in der Diabetesbehandlung | 1 | Investing.com Deutsch | ||
| KADIMASTEM Aktie jetzt für 0€ handeln | |||||
| 31.01. | NLS Pharmaceutics Stock Rises 29% Following Merger Announcement With Kadimastem | - | RTTNews | ||
| 31.01. | Kadimastem gets shareholder backing for NLS merger, advancing once-thwarted push for Nasdaq listing | 1 | FierceBiotech | ||
| 31.01. | NLS and Kadimastem move forward with merger plans | 1 | Investing.com | ||
| 31.01. | Kadimastem Ltd.: Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics | 915 | PR Newswire | ZURICH and NESS ZIONA, Israel, Jan. 31, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| 30.12.24 | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger | 506 | PR Newswire | The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and a focus on advancing its allogeneic cell therapy platform... ► Artikel lesen | |
| 19.12.24 | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment | 339 | ACCESS Newswire | This submission comes after successful INTERACT meeting with the FDA earlier this year.NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025 ZURICH, SWITZERLAND AND NESS... ► Artikel lesen | |
| 04.11.24 | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement | 471 | ACCESS Newswire | ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA") ("Kadimastem")... ► Artikel lesen | |
| 29.07.24 | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge | 433 | ACCESS Newswire | The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy... ► Artikel lesen | |
| 18.07.24 | Pluri Inc.: Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates | 765 | GlobeNewswire (Europe) | HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,555 | +0,68 % | Biotech Report: Evotec und Qiagen leichter, US-Sektor verliert | (shareribs.com) Frankfurt / New York 17.06.2025 - Biotech-Aktien bewegen sich im deutschen Handel überwiegend nach unten. So korrigieren unter anderem Evotec und Qiagen. An der Wall Street rutscht der... ► Artikel lesen | |
| EVOTEC | 6,544 | -0,37 % | Nächste Übernahme und bahnbrechende Forschung - BioNTech, CureVac, Evotec, Vidac Pharma | Am Mittwoch konnten die Chefunterhändler von China und der USA bei ihren Verhandlungen in London Vollzug melden. Die dort getroffenen Vereinbarungen werden von den jeweiligen Staatschef Xi Jinping und... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,970 | +0,38 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| CARIS LIFE SCIENCES | 27,015 | -2,93 % | Caris Life Sciences Prices IPO Of About 23.53 Mln Shares At $21.00/shr | WASHINGTON (dpa-AFX) - Caris Life Sciences (Caris) announced that it has priced its initial public offering of about 23.53 million shares of its common stock at a public offering price of $21.00... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 29,190 | -0,41 % | Wolfe Research initiates Avidity Biosciences stock with outperform rating | ||
| SUMMIT THERAPEUTICS | 20,200 | +0,20 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| BIONTECH | 92,85 | +3,17 % | CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech | ||
| TARSUS PHARMACEUTICALS | 40,710 | -0,90 % | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | ||
| BEAM THERAPEUTICS | 16,700 | -1,65 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,950 | -2,85 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| MODERNA | 22,215 | +1,53 % | Moderna erhält FDA-Zulassung für erweiterten RSV-Einsatz | Moderna hat für seinen RSV-Impfstoff mRESVIA die US-Zulassung auf Personen im Alter von 18 bis 59 Jahren mit erhöhtem Krankheitsrisiko ausgeweitet. Bislang war der Impfstoff in den USA nur für Menschen... ► Artikel lesen | |
| VERA THERAPEUTICS | 21,030 | +0,57 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 35,550 | -43,88 % | Regencell Bioscience Holdings Ltd - 6-K, Report of foreign issuer | ||
| CUREVAC | 4,706 | -0,97 % | SONDERMELDUNG bei CureVac: Insider kaufen massenhaft Anteile - Dringend vor dem Wochenende handeln! | ||
| PRAXIS PRECISION MEDICINES | 42,830 | -0,30 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen |
KADIMASTEM LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KADIMASTEM LTD finden Sie auf Wallstreet Online.